Gene therapy for pancreatic cancer

Hepato-Gastroenterology

Volumn 48, Issue 40, 2001, Pages 957-961

  Kasuya, H ^a   Nomoto, S ^a   Kimata, H ^a   Harada, A ^a   Takeda, S ^a   Hayashi, S ^a   Nakao, A ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene therapy; HSV; K ras; ONYX 015; Pancreatic cancer

Indexed keywords

5 DEOXY 5 FLUOROURIDINE; ALKALINE PHOSPHATASE; ANTISENSE OLIGONUCLEOTIDE; BENZOIC ACID DERIVATIVE; BENZOIC ACID MUSTARD; CA 19-9 ANTIGEN; CARBOXYPEPTIDASE A; CARBOXYPEPTIDASE G2; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B1; CYTOSINE DEAMINASE; ETOPOFOS; ETOPOSIDE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GANCICLOVIR DERIVATIVE; GANCICLOVIR TRIPHOSPHATE; GENE PRODUCT; K RAS PROTEIN; METHOTREXATE; METHOTREXATE ALANINE; METHOTREXATE DERIVATIVE; MUCIN 1; ONCOLYTIC VIRUS; PHOSPHORAMIDE MUSTARD; PROTEIN P53; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

CANCER DIAGNOSIS; CANCER STAGING; CELL KILLING; DNA VECTOR; EARLY DIAGNOSIS; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC CODE; HUMAN; LIVER METASTASIS; MODEL; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS RESECTION; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR GROWTH;

ANIMALS; DNA REPLICATION; GENE THERAPY; GENES, P53; GENES, RAS; HUMANS; PANCREATIC NEOPLASMS; PRODRUGS; PROMOTER REGIONS (GENETICS);

EID: 0034893730     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Problems in pancreatic cancer surgery
2. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinoma
3. Abnormalities of p53 tumor suppressor gene in preinvasive pancreatic adenocarcinoma
4. Abnormalities of p53 tumor suppressor gene in human pancreatic cancer
5. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
6. Cooperative binding of Smad proteins to two adjacent DNA elements in the plasminogen activator inhibitor-1 promoter mediates transforming growth factor beta-induced smad-dependent transcriptional activation
7. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer
8. DPC-4 a candidate tumour suppressor gene at human chromosome 18q21.1
9. Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/restriction fragment length polymorphism analysis
10. Clinical application of K-ras oncogene mutations in pancreatic carcinoma: Detection of micrometastase
11. Prevention of orthotopic human lung cancer growth by intratracheal institution of a retroviral antisense K-ras constract
12. The inhibitory effect of antisense oligonucleotides on the growth of human pancreatic adenocarcinoma cell lines
13. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutations but not those without Ki-ras mutations
14. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity
15. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer
16. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene
17. A codon 248 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53
18. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors
19. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene
20. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer
21. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer
22. In vivo adenovirus-mediated prodrug genetherapy for carcinoembryonic antigen-producing pancreatic cancer
23. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma
24. Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme
25. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer
26. Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy
27. Pancreaticobiliary cancer: The future aspects of medical oncology
28. Advances in the treatment of patients with pancreatic cancer: Improvement in symptom and survival time
29. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
30. Adenovirus early region 1B 58,000-dalton tumor antigen is physically associated with an early region 4 25,000-dalton protein in productively infected cells
31. Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53
32. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein
33. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
34. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus
35. Gene therapy with Adv-IL-2 in unresectable digestive cancer: Phase I-II study, intermediate report
36. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma
37. ONYX-015: Clinical data are encouraging
38. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells
39. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo